Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Trial Profile

Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Busulfan (Primary) ; Cladribine (Primary) ; Fludarabine (Primary) ; Filgrastim; Methotrexate
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2014 Planned primary completion date changed from 1 Dec 2019 to 1 Oct 2019, as per ClinicalTrials.gov record.
    • 27 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
    • 01 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top